Impact of dabigatran on a large panel of routine or specific coagulation assays

Summary

Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of the study was to determine which coagulation assay(s) could be used to assess the impact of dabig-atran on secondary haemostasis. Dabigatran was spiked at concentrations ranging from 4.7 ng/ml to 943.0 ng/ml in pooled citrated human platelet-poor plasma. The following clotting assays were performed: prothrombin time (PT); activated partial thromboplastin time (aPTT); thrombin time (TT); ecarin clotting time (ECT); ecarin chromo-genic assay (ECA); prothrombinase-induced clotting time (PiCT); activated clotting time (ACT); Hemoclot Thrombin Inhibitor (HTI) and thrombin generation assay (TGA). A concentration-dependent prolongation of PT, dPT, and aPTT was observed with aPTT being the more sensitive test. The results varied mostly due to the clotting reagent. HTI, ECT and TGA were the most sensitive tests but are not available 24 hours a day. In addition, HTI showed a linear correlation with a good reproduci-bility. Dabigatran induced a concentration-dependent delay and inhibition of tissue factor-induced TGA. Cut-offs related with higher risk of bleedings or thrombosis were defined for each reagent of aPTT and HTI. In conclusion, aPTT could be used for the monitoring of dabigatran and as screening test for the risk of overdose. However, because of its higher sensitivity, good reproducibility, excellent linear correlation at all doses, its simplicity of use, and possibilities of automation, HTI should be considered as the gold-standard.

Keywords

Dabigatran - monitoring - Hemoclot Thrombin Inhibitor - new oral anticoagulant - bleeding - thrombosis

• References

• 1 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 3 Suppl 204S-233S.
• 2 Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28: 1354-1373.
• 3 EMA. Summary of Product Characterisitic. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/epar_-_Product_information/human/000829/WC500041059.pdf Accessed on October 23, 2011
• 4 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
• 5 Wolowacz SE, Roskell NS, Plumb JM. et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
• 6 EMA. CHMP post-authorisation summary of positive opinion for Pradaxa 14. April 2011 Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Summary-of-opinion/human/000829/WC500105283.pdf Accessed on October 23, 2011
• 7 Aalbers J, Bryer A, Klug E. FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation. Cardiovasc J Afr 2010; 21: 341.
• 8 Stangier J, Stahle H, Rathgen K. et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59.
• 9 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31: 326-343.
• 10 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
• 11 Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabig-atran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
• 12 Shelley Wood. Deaths prompt dabigatran safety advisory in Japan. theheart.org. [Clinical Conditions > Arrhythmia/EP > Arrhythmia/EP]. Aug 17 2011 Accessed at http://www.theheart.org/article/1264365.do on Nov 9, 2011
• 13 EMA. Update on safety of Pradaxa. Available at: http://emea.europa.eu/ema/index.jsp?and=pages/news_and_events/news/2011/11/news_detail_001390.jsp&mid=wc0b01ac05800d5c1 Accessed on December 26, 2011
• 14 Government A. Australian Public Assessment Report for Dabigatran etexilate mesilate. Available at: http://www.tga.gov.au/pdf/auspar/auspar-pradaxa.pdf Accessed on November 9, 2011
• 15 Heidbuchl H, Thijs V, Verhamme P. et al. Educational material as part of the EMA Risk Minimisation Plan – at this stage approved by German and Dutch authorities. Available at: http://www.thrombosisguidelinesgroup.be/sites/default/files/Pradaxa_Protocol_questions_final_Sept_2011.pdf
• 16 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects. Circulation 2011; 124: 1573-1579.
• 17 Levi M, Eerenberg E, Kampuisen PW. Bleed ingrisk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011; 09: 1705-1712.
• 18 Freyburger G, Macouillard G, Labrouche S. et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465.
• 19 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
• 20 Stangier J, Rathgen K, Stahle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
• 21 Wienen W, Stassen JM, Priepke H. et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-162.
• 22 Lindahl TL, Baghaei F, Blixter if. et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2010; 105: 371-378.
• 23 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 24 Robert S, Ghiotto J, Pirotte B. et al. Is throm bingeneration the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?. Pharmacol Res 2009; 59: 160-166.
• 25 Lange U, Nowak G, Bucha E. Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 2003; 33: 184-191.
• 26 Pengo V, Crippa L, Falanga A. et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
• 27 Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost 2010; 08: 621-626.
• 28 Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost 2010; 08: 627-630.
• 29 Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-772.
• 30 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 31 Schulman S, Kearon C, Kakkar AK. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
• 32 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
• 33 Ezekowitz MD, Reilly PA, Nehmiz G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-1426.
• 34 Samama MM, Martinoli JL, LeFlem L. et al. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
• 35 Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353-1358.
• 36 Calatzis A, Peetz D, Haas S. et al. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008; 130: 446-454.
• 37 Samama MM, Le Flem L, Guinet C. et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 05: 2554-2556.
• 38 Wagenvoord RJ, Deinum J, Elg M. et al. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost 2010; 08: 1281-1289.
• 39 Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85: 947-950.
• 40 Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006; 96: 547-552.
• 41 Kitchens CS. To bleed or not to bleed? Is that the question for the PTT?. J Thromb Haemost 2005; 03: 2607-2611.
• 42 Lippi G, Salvagno GL, Ippolito L. et al. Shortened activated partial thromboplas-tin time: causes and management. Blood Coagul Fibrinolysis 2010; 21: 459-463.
• 43 Samama M. Maladies de l'hémostase liées à une atteinte rénale. Samama M. editor Hémorragies et thromboses: Du diagnostic au traitement. 2 ed. Elsevier Masson; 2009: 107-108.
• 44 Samama MM, Amiral J, Guinet C. et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078-1079.
• 45 Godier A, Miclot A, Le Bonniec B. et al. Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model. Anesthesiology 2012; 116: 94-102.